Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

nts, short-term investments and net working capital of $5,635,365, $6,825,190 and $9,088,712, respectively. The Company currently believes that it has adequate financial resources to continue into the fourth quarter of fiscal 2008 based on planned research and development expenditures and operating costs.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to Follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

INTERIM BALANCE SHEETS

(Unaudited)

-------------------------------------------------------------------------

May 31, November 30,

2008 2007

$ $

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents 8,543,124 5,635,365

Short-term investments - 6,825,190

Receivables 185,672 230,126

Refundable tax credits 600,000 400,000

Prepaid expenses
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... In preparation for VARTECH 2014, 2FA, Inc., ... focused on authentication and SSO announced today that their ... generate a OTP through the presentation of an RFID ... RFID authentication, 2FA,s solutions have leveraged the existence of ... RFID authentication is broadly deployed in healthcare and other ...
(Date:9/15/2014)... Sept. 15, 2014   Global Science & ... scientific products and services for satellite and weather ... for Integrated Services (OASIS) from the General Services ... selected to provide the government best-value solutions for ... (SB) category in Pool 4. The OASIS SB ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)...  iVinci Health LLC, the company behind the healthcare ... branded as VisitPay®, has successfully closed $5 million in ... a new extension to VisitPay® – an online Payment ... way for patients to manage their medical bills and ... their families. The new round of funding, ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... FRANCISCO, Calif., Nov. 1, 2010 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today announced that the company, formerly known ... Board under the ticker symbol (VXGN), has been renamed ...
... Nov. 1, 2010 Amgen (Nasdaq: AMGN ) ... Ph.D., will urge members of a U.S. Food and Drug ... to establish approval standards that ensure patient safety and follow ... policy will follow," Dr. Miletich said.  "Amgen believes biosimilars have ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... will allow us to better understand how the ... scenarios and provide the type of environmental data ... and siting of protected areas," said Paula Whitfield, ... Coastal Ocean Science (NCCOS) and lead author of ... within the temperate-tropical transition zone, where historically, both ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Study finds warming Atlantic temperatures could increase range of invasive species 2
... D.C., November 21, 2010 -- For centuries, hunters have imitated ... carving wooden bird calls. Now a team of physicists at ... characteristics of real bird song with a simple physical model ... know if you [could] build a simple device, which has ...
... baby,s first blurted "bowl!," for the word "ball" to the ... vocalizations is one of humankind,s most remarkable attributes -- and ... Not so for people who are afflicted with ... stigma of affected speech. Nor so for engineering professor Michael ...
... , Researchers in the United States have developed a ... from a patient,s own bone marrow. The research, published ... suffering from abnormally developed bladders, but also represents another ... research, led by Dr Arun Sharma and Earl Cheng ...
Cached Biology News:Simple rubber device mimics complex bird songs 2Air flows in mechanical device reveal secrets of speech pathology 2New study into bladder regeneration heralds organ replacement treatment 2
Request Info...
...
... High Resolution - Efficiently ... 50 to 1000 bp. ... sizing PCR fragments, small ... restriction enzyme digestion, and ...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: